Skip to content

US · PRME · BIOTECHNOLOGY

Prime Medicine, Inc. (PRME) intrinsic value and stock valuation

$3.55as of 2026-11-21 · Mkt cap 556.3M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Prime Medicine, Inc. DCF and intrinsic value

InvestorsCraft values PRME with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PRME’s statements →

Prime Medicine, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02141 primemedicine.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$4.63M-2.3% 5y CAGRd
20192025
Net income
-$-201.14M
20192025
Free cash flow
-$-167.09M
20192025
Total equity
$120.9M+29.3% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$4.63M$2.98M$0.00$0.00$0.00
Operating income-$-208.35M-$-202.47M-$-204.79M-$-116.54M-$-84.47M
Net income-$-201.14M-$-195.88M-$-198.13M-$-121.82M-$-165.37M
EPSd-$-1.35M-$-1.65M-$-2.18M-$-1.25M-$-1.73M
Operating cash flow-$-162.56M-$-122.86M-$-165.41M-$-131.83M-$-34.08M
Capital expenditure-$-4.53M-$-7.29M-$-8.72M-$-16.09M-$-4.15M
Free cash flow-$-167.09M-$-130.16M-$-174.14M-$-147.92M-$-38.23M
Total assets$342.7M$297.5M$193.9M$360.3M$301.9M
Total debt$116.4M$40.8M$13.6M$28.8M$10.4M
Net debt$53.4M-$-141.68M-$-27.94M-$-158.88M-$-175.01M
Total equity$120.9M$153.2M$133.1M$316.3M$239.6M
Cash and short-term investments$177.7M$190.4M$121.7M$293.9M$269.6M
Income statement
20252024202320222021
Revenue$4.63M$2.98M$0.00$0.00$0.00
Cost of revenue$7.32M$0.00$0.00$0.00$0.00
Gross profit-$-2.69M$2.98M$0.00$0.00$0.00
Research and development expenses$160.6M$155.3M$147.9M$86.7M$70.6M
Selling, general and administrative expenses$52.4M$50.2M$43.4M$29.8M$13.9M
Other expenses-$-7.32M$0.00$13.5M$0.00$0.00
Operating expenses$205.7M$205.5M$204.8M$116.5M$84.5M
Cost and expenses$213M$205.5M$204.8M$116.5M$84.5M
Interest income$4.15M$3.52M$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$5.38M$6.13M$4.65M$2.22M$570K
Ebitda-$-195.76M-$-189.75M-$-186.64M-$-120.55M-$-165.28M
Operating income-$-208.35M-$-202.47M-$-204.79M-$-116.54M-$-84.47M
Total other income/expenses, net$7.21M$6.58M$6.38M-$-6.22M-$-81.38M
Income before tax-$-201.14M-$-195.88M-$-198.41M-$-122.77M-$-165.85M
Income tax expense$0.00$0.00-$-280K-$-950K-$-490K
Net income-$-201.14M-$-195.88M-$-198.13M-$-121.82M-$-165.37M
Weighted average shares outstanding$148.8M$118.6M$91M$97.2M$95.7M
Weighted average diluted shares outstanding$148.8M$118.6M$91M$97.2M$95.7M
Balance sheet
20252024202320222021
Cash and short-term investments$177.7M$190.4M$121.7M$293.9M$269.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$181.3M$211.9M$143M$296.6M$270.6M
Property, plant and equipment, net$146.8M$71.6M$36.6M$48.6M$15.7M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$161.4M$85.6M$50.9M$63.7M$31.3M
Total assets$342.7M$297.5M$193.9M$360.3M$301.9M
Accounts payable$8.89M$11.4M$19.5M$4.33M$1.44M
Short-term debt$8.14M$3.61M$9.28M$11.7M$7.34M
Deferred revenue$7.82M$7.09M$0.00$0.00$0.00
Total current liabilities$37.5M$38M$56.4M$26.7M$58M
Long-term debt$108.3M$37.2M$4.36M$17.1M$3.07M
Deferred revenue, non-current$0.00$63.2M$0.00$0.00$0.00
Total non-current liabilities$184.4M$106.4M$4.36M$17.3M$4.31M
Capital lease obligations$8.14M$40.8M$13.6M$28.8M$10.4M
Total liabilities$221.9M$144.4M$60.8M$44M$62.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-888.35M-$-687.21M-$-491.33M-$-293.2M-$-171.38M
Accumulated other comprehensive income (loss)$80K$0.00-$-10K-$-380K-$-30K
Total equity$120.9M$153.2M$133.1M$316.3M$239.6M
Total investments$114.7M$7.97M$80.1M$106.3M$84.2M
Total debt$116.4M$40.8M$13.6M$28.8M$10.4M
Net debt$53.4M-$-141.68M-$-27.94M-$-158.88M-$-175.01M
Cash flow statement
20252024202320222021
Net income-$-201.14M-$-195.88M-$-198.13M-$-121.82M-$-165.37M
Depreciation and amortization$5.38M$6.13M$4.65M$2.22M$570K
Stock-based compensation$29.3M$26.1M$13.9M$6.46M$1.75M
Change in working capital-$-5.34M$31.1M$2.65M-$-35.4M$31.2M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1M-$-5.26M$9.14M$2.46M$1.19M
Net cash provided by operating activities-$-162.56M-$-122.86M-$-165.41M-$-131.83M-$-34.08M
Investments in property, plant and equipment-$-4.53M-$-7.29M-$-8.72M-$-16.09M-$-4.15M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-108.76M$68.5M$18.7M-$-47.1M-$-73.63M
Common stock issued$139.5M$170.1M$660K$185.3M$270.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$151.5M$195.9M$660K$181.5M$269.3M
Net change in cash-$-119.81M$141.5M-$-146.05M$2.57M$161.6M
Cash at end of period$76.7M$196.5M$55.1M$201.1M$198.5M
Operating cash flow-$-162.56M-$-122.86M-$-165.41M-$-131.83M-$-34.08M
Capital expenditure-$-4.53M-$-7.29M-$-8.72M-$-16.09M-$-4.15M
Free cash flow-$-167.09M-$-130.16M-$-174.14M-$-147.92M-$-38.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Prime Medicine, Inc.

        Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

        CEO
        Allan Reine
        Employees
        146
        Beta
        2.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Prime Medicine, Inc. (PRME)?

        Prime Medicine, Inc. (PRME) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PRME undervalued?

        PRME trades at a price of $3.55 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.